One Blood Test, Multiple Diseases: A New Era for Early Detection

LOS ANGELES, CA – May 05, 2026 – A groundbreaking study published in the Proceedings of the National Academy of Sciences (PNAS) has validated a revolutionary liquid biopsy platform capable of detecting multiple cancers, liver diseases, and other organ abnormalities from a single, low-cost blood test. The technology, developed by Los Angeles-based EarlyDiagnostics, Inc., could represent a significant paradigm shift in preventative medicine, moving beyond single-disease screening to a more holistic and accessible form of health monitoring.

The peer-reviewed study validates the company’s proprietary MethylScan™ platform, which demonstrated strong performance in a trial involving over 1,000 patient samples. This scientific validation provides a powerful foundation for a technology aiming to conquer one of healthcare's biggest challenges: detecting deadly diseases early enough to make a difference.

“This publication validates the scientific foundation of our platform and supports our vision of a single, affordable blood test for early disease detection,” said Dr. Jasmine Zhou, Co-founder and CEO of EarlyDx and a professor at UCLA. “We are focused on advancing validation and expanding strategic partnerships to bring this technology into broader clinical use.”

The Science Behind Low-Cost Sequencing

At the heart of the MethylScan™ platform is an innovative approach to analyzing DNA methylation - chemical tags on DNA that can indicate the presence of disease. While other liquid biopsy tests analyze cell-free DNA (cfDNA) shed by tumors into the bloodstream, they often struggle with a high signal-to-noise ratio, as the vast majority of cfDNA comes from healthy blood cells. This necessitates deep, and therefore expensive, genetic sequencing, with leading multi-cancer early detection (MCED) tests costing upwards of $950.

EarlyDiagnostics’ method sidesteps this challenge. The platform uses Methylation-Sensitive Restriction Enzymes (MSRE) to specifically target and break down the abundant, hypomethylated “background noise” from healthy blood cells. This process effectively enriches the sample for the hypermethylated cfDNA more likely to originate from diseased tissue, dramatically reducing sequencing requirements. The result, as detailed in the PNAS paper, is a highly cost-efficient assay with an estimated sequencing cost of less than $20 per sample. While additional costs for reagents, logistics, and sample handling bring the total test price higher, this low sequencing overhead remains a critical differentiator for the platform’s scalability.

This cost-efficiency is a critical differentiator in a market where widespread adoption has been hampered by high prices and limited reimbursement. By making the test affordable, EarlyDx aims to unlock the potential for population-wide screening.

Validated Performance Across a Spectrum of Diseases

The PNAS study, which evaluated 1,061 patient samples, showcased the platform's robust and versatile capabilities. For multi-cancer detection across liver, lung, ovarian, and stomach cancers, the test achieved an Area Under the Receiver Operating Characteristic Curve (AUROC) - a key measure of diagnostic accuracy - of 0.938. It demonstrated a sensitivity of 63.3% at a high specificity of 98.0%. Critically for early detection, its performance remained strong for Stage I and II cancers, with 55.3% sensitivity at the same specificity.

Beyond its multi-cancer capabilities, the test demonstrated exceptional utility in liver disease:
* Liver Cancer Surveillance: In a high-risk cohort, the test achieved 79.6% sensitivity for detecting hepatocellular carcinoma (HCC) at 90.4% specificity.
* Liver Disease Classification: It successfully distinguished between different types of liver disease, including viral hepatitis and metabolic-associated liver disease, in about 85% of patients.
* Tissue-of-Origin: When a cancer signal was detected, the test correctly identified the tissue of origin with an average accuracy of 91.7%, a crucial step in guiding physicians to the correct follow-up diagnostics.

The platform's clinical foundation is further strengthened by external validation. In a multi-site, blinded study presented at The Liver Meeting® (AASLD 2025), Dr. Neehar Parikh of the University of Michigan demonstrated the test's strong performance in detecting early-stage liver cancer, providing real-world evidence of its clinical utility.

Navigating the Commercial Landscape

EarlyDiagnostics is entering the rapidly growing multi-cancer early detection market, projected to exceed $5 billion by 2034. While facing established competitors like Grail and Guardant Health, its strategy appears uniquely focused on overcoming the primary barriers to adoption: cost and reimbursement.

The company is already making significant commercial headway. It operates a CLIA-certified laboratory, a federal requirement for performing clinical diagnostic testing in the U.S. More importantly, it has secured key reimbursement infrastructure for its HCC test, including a specific Proprietary Laboratory Analysis (PLA) code (0565U) and a CMS pricing determination. This achievement addresses a major hurdle that has slowed the market entry of other novel diagnostics and positions EarlyDx for faster clinical integration, at least for its initial liver cancer application.

By proving its utility and securing a pathway to payment for one key disease, the company is building a strategic beachhead from which to expand. With its highly efficient sequencing profile and “pan-disease” capabilities, MethylScan™ is well-positioned to appeal to payers and public health systems focused on affordable preventative care and population health management.

A Future of Holistic Health Monitoring

The true promise of MethylScan™ may lie in its ability to function as a comprehensive “health radar.” By analyzing methylation patterns across the genome, the test can detect signals of organ-specific stress or damage far beyond oncology. This capability opens the door to a future where an annual blood test could provide a comprehensive snapshot of a person’s health, flagging early signs of chronic conditions long before symptoms appear.

EarlyDiagnostics is actively pursuing this broader vision. The company has additional validation programs underway to expand its platform's clinical applications into the early detection of lung and ovarian cancer, building on the promising data from the PNAS study. As the platform's machine learning algorithms are fed more data, their ability to discern subtle patterns of disease is expected to improve continuously.

With peer-reviewed scientific validation, mounting clinical evidence, and a clear commercialization strategy centered on accessibility, EarlyDiagnostics is advancing a technology that could fundamentally change how we approach disease. The prospect of a single, affordable blood test for early detection of a wide range of conditions is no longer just a theoretical goal but an advancing reality.

Editorial Note (May 06, 2026): A previous version of this article incorrectly implied that the total cost of the MethylScan™ test was less than $20. This figure specifically refers to the sequencing cost per sample. The text has been updated to clarify that overall test pricing includes additional operational and reagent expenses.